Do analysts prefer PRPH or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, AMPE or HEPA?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is AMPE or HEPA more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Hepion Pharmaceuticals N/A -812.56% -207.31%

Which has stronger valuation and earnings, AMPE or WINT?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Windtree Therapeutics N/A N/A -$1.79M -$8.77 N/A

Is AMPE or WINT more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Windtree Therapeutics N/A -207.34% -50.19%

Which has preferable valuation & earnings, AMPE or BPTSY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is AMPE or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Biophytis N/A N/A N/A

Do analysts prefer AMPE or CERO?

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 239,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Ampio Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation and earnings, AMPE or CERO?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A CERo Therapeutics N/A N/A -$8.30M -$71.01 N/A

Is AMPE or CERO more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A CERo Therapeutics N/A N/A -209.40%

Ampio Pharmaceuticals (AMPE) Competitors

$0.18 0.00 (0.00%)

As of 06/12/2026

Compare

AMPE vs. PRPH, HEPA, WINT, BPTSY, and CERO

Should you buy Ampio Pharmaceuticals stock or one of its competitors? MarketBeat compares Ampio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ampio Pharmaceuticals include ProPhase Labs (PRPH), Hepion Pharmaceuticals (HEPA), Windtree Therapeutics (WINT), Biophytis (BPTSY), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry.

How does Ampio Pharmaceuticals compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Ampio Pharmaceuticals	Neutral

Ampio Pharmaceuticals has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.10	-$53.36M	-$3.90	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Ampio Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Ampio Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Ampio Pharmaceuticals	N/A	N/A	N/A

ProPhase Labs has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Ampio Pharmaceuticals beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Hepion Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Ampio Pharmaceuticals (NYSE:AMPE) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Windtree Therapeutics	Neutral

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Windtree Therapeutics	N/A	-207.34%	-50.19%

Summary

Ampio Pharmaceuticals and Windtree Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Ampio Pharmaceuticals (NYSE:AMPE) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Biophytis	Neutral

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Ampio Pharmaceuticals (NYSE:AMPE) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
CERo Therapeutics	N/A	N/A	-209.40%

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 239,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Ampio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

In the previous week, CERo Therapeutics had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
CERo Therapeutics	Neutral

Summary

CERo Therapeutics beats Ampio Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPE vs. The Competition

Export

Metric	Ampio Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$208K	$960.97M	$6.74B	$23.32B
Dividend Yield	N/A	4.84%	2.67%	4.05%
P/E Ratio	-0.02	1.44	23.90	31.59
Price / Sales	N/A	128.90	511.88	20.84
Price / Cash	N/A	20.06	27.48	18.65
Price / Book	0.05	8.02	10.47	4.70
Net Income	-$8.63M	-$4.88M	$3.56B	$1.08B
7 Day Performance	N/A	4.00%	0.66%	1.28%
1 Month Performance	N/A	3.52%	1.90%	3.33%
1 Year Performance	57.71%	46.78%	24.86%	23.15%

Ampio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PRPH ProPhase Labs	N/A	$0.14 -1.2%	N/A	-97.4%	$817K	$5.06M	N/A	130	Gap Down
HEPA Hepion Pharmaceuticals	N/A	$0.06 -4.8%	N/A	-18.0%	$686K	N/A	N/A	20	Gap Down
WINT Windtree Therapeutics	N/A	$0.02 +2.0%	N/A	-97.3%	$679K	N/A	N/A	30
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRPH, HEPA, WINT, BPTSY, and CERO

How does Ampio Pharmaceuticals compare to ProPhase Labs?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Summary

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. PRPH, HEPA, WINT, BPTSY, and CERO

How does Ampio Pharmaceuticals compare to ProPhase Labs?

Does the media prefer PRPH or AMPE?

Which has better earnings & valuation, PRPH or AMPE?

Is PRPH or AMPE more profitable?

Which has more volatility & risk, PRPH or AMPE?

Do insiders & institutionals have more ownership in PRPH or AMPE?

Do analysts prefer PRPH or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Is AMPE or HEPA more profitable?

Which has more risk & volatility, AMPE or HEPA?

Which has better valuation and earnings, AMPE or HEPA?

Does the media prefer AMPE or HEPA?

Do insiders and institutionals believe in AMPE or HEPA?

Summary

How does Ampio Pharmaceuticals compare to Windtree Therapeutics?

Does the media favor AMPE or WINT?

Do insiders & institutionals believe in AMPE or WINT?

Which has stronger valuation and earnings, AMPE or WINT?

Which has more risk & volatility, AMPE or WINT?

Is AMPE or WINT more profitable?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Which has more risk and volatility, AMPE or BPTSY?

Is AMPE or BPTSY more profitable?

Which has preferable valuation & earnings, AMPE or BPTSY?

Do institutionals and insiders hold more shares of AMPE or BPTSY?

Does the media refer more to AMPE or BPTSY?

Summary

How does Ampio Pharmaceuticals compare to CERo Therapeutics?

Which has more risk and volatility, AMPE or CERO?

Is AMPE or CERO more profitable?

Do insiders & institutionals have more ownership in AMPE or CERO?

Do analysts prefer AMPE or CERO?

Which has higher valuation and earnings, AMPE or CERO?

Does the media favor AMPE or CERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools